
Steven P Marso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12104959/publications.pdf Version: 2024-02-01



4

#	Article	IF	CITATIONS
1	Outcomes of retrograde chronic total occlusion percutaneous coronary intervention: A report from the OPEN TO registry. Catheterization and Cardiovascular Interventions, 2021, 97, 1162-1173.	1.7	19
2	Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 595-605.	11.4	61
3	Development of a hypoglycaemia risk score to identify highâ€risk individuals with advanced type 2 diabetes in DEVOTE. Diabetes, Obesity and Metabolism, 2020, 22, 2248-2256.	4.4	8
4	Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. Lancet Diabetes and Endocrinology,the, 2020, 8, 880-893.	11.4	86
5	Management of Percutaneous Coronary Intervention Complications. Circulation: Cardiovascular Interventions, 2020, 13, e008962.	3.9	46
6	Effects of Liraglutide on CardiovascularÂOutcomes in Patients With Diabetes With or Without HeartÂFailure. Journal of the American College of Cardiology, 2020, 75, 1128-1141.	2.8	53
7	Risk of severe hypoglycaemia and its impact in type 2 diabetes in <scp>DEVOTE</scp> . Diabetes, Obesity and Metabolism, 2020, 22, 2241-2247.	4.4	11
8	Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). Applied Health Economics and Health Policy, 2019, 17, 615-627.	2.1	10
9	A Detailed Analysis of Perforations During Chronic Total Occlusion Angioplasty. JACC: Cardiovascular Interventions, 2019, 12, 1902-1912.	2.9	58
10	Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). Diabetes, Obesity and Metabolism, 2019, 21, 1625-1633.	4.4	18
11	Quality of Life Changes After Chronic Total Occlusion Angioplasty in Patients With Baseline Refractory Angina. Circulation: Cardiovascular Interventions, 2019, 12, e007558.	3.9	29
12	Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes. Diabetes Therapy, 2018, 9, 551-564.	2.5	7
13	DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK. Diabetes Therapy, 2018, 9, 1217-1232.	2.5	11
14	Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). American Journal of Cardiology, 2018, 121, 1467-1470.	1.6	25
15	DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia, 2018, 61, 58-65.	6.3	124
16	Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia, 2018, 61, 48-57.	6.3	126
17	Impact of subintimal plaque modification procedures on health status after unsuccessful chronic total occlusion angioplasty. Catheterization and Cardiovascular Interventions, 2018, 91, 1035-1042.	1.7	48

18 Revascularization Approaches. , 2018, , 337-354.

#	Article	IF	CITATIONS
19	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation, 2018, 138, 2884-2894.	1.6	82
20	Treating Leave Behind Lesions. Circulation: Cardiovascular Interventions, 2018, 11, e007367.	3.9	0
21	Relationship between left main coronary artery plaque burden and nonleft main coronary atherosclerosis. Coronary Artery Disease, 2018, 29, 397-402.	0.7	3
22	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease. Circulation, 2018, 137, 2179-2183.	1.6	80
23	Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial. Diabetes and Vascular Disease Research, 2018, 15, 465-468.	2.0	22
24	Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. Diabetes Care, 2018, 41, 1783-1791.	8.6	82
25	Impact of TCFA on Unanticipated IschemicÂEvents in Medically Treated Diabetes Mellitus. JACC: Cardiovascular Imaging, 2017, 10, 451-458.	5.3	34
26	Costs Associated With Access Site andÂSame-Day Discharge Among MedicareÂBeneficiaries Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2017, 10, 342-351.	2.9	92
27	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2017, 376, 890-892.	27.0	69
28	The Outcomes, Patient Health Status, and Efficiency IN Chronic Total Occlusion Hybrid Procedures registry. Coronary Artery Disease, 2017, 28, 110-119.	0.7	45
29	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 723-732.	27.0	480
30	Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication. JACC: Cardiovascular Interventions, 2017, 10, 712-724.	2.9	56
31	Liraglutide and Renal Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 839-848.	27.0	903
32	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 1228-1239.	27.0	1,455
33	Early Procedural and Health Status Outcomes After Chronic Total OcclusionÂAngioplasty. JACC: Cardiovascular Interventions, 2017, 10, 1523-1534.	2.9	234
34	Safety of Degludec versus Glargine in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 1994-1996.	27.0	5
35	LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ. Diabetology and Metabolic Syndrome, 2016, 8, 37.	2.7	9
36	Association between health status and longâ€ŧerm mortality after percutaneous revascularization of peripheral artery disease. Catheterization and Cardiovascular Interventions, 2016, 87, 1149-1155.	1.7	9

#	Article	IF	CITATIONS
37	The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation inÂBleeding Rates Following PercutaneousÂCoronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 771-779.	2.9	17
38	Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non–ST Elevation Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 197-205.	2.2	52
39	Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in) Tj ETQq1 1 Journal, 2016, 179, 175-183.	0.784314 2.7	rgBT /Overloc 58
40	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 1834-1844.	27.0	3,898
41	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 311-322.	27.0	5,070
42	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. American Heart Journal, 2016, 174, 103-110.	2.7	82
43	Inpatient or Outpatient Status for Elective Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, e003699.	3.9	5
44	Influence of Total Coronary Occlusion on Clinical Outcomes (from the Bypass Angioplasty) Tj ETQq0 0 0 rgBT /C	verlock 10	0 Tf 50 462 To
45	How to Fix Common Problems Encountered in CTO PCI: The Expanded Hybrid Approach. , 2016, , 141-159.		1
46	Procedural failure of chronic total occlusion percutaneous coronary intervention: Insights from a multicenter US registry. Catheterization and Cardiovascular Interventions, 2015, 85, 1115-1122.	1.7	52
47	State-of-the-Art: Hypo-responsiveness to Oral Antiplatelet Therapy in Patients with Type 2 Diabetes Mellitus. Current Cardiovascular Risk Reports, 2015, 9, 4.	2.0	16
48	Usefulness of Coronary Atheroma Burden to Predict Cardiovascular Events in Patients Presenting With Acute Coronary Syndromes (from the PROSPECT Study). American Journal of Cardiology, 2015, 116, 1672-1677.	1.6	16
49	Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Metaâ€Analysis and Systematic Review. Journal of the American Heart Association, 2015, 4, e002137.	3.7	52
50	Predictors of Plaque Rupture Within Nonculprit Fibroatheromas in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Imaging, 2015, 8, 1180-1187.	5.3	28
51	Percutaneous Intervention of Circumflex Chronic Total Occlusions Is Associated With Worse Procedural Outcomes: Insights From a Multicentre US Registry. Canadian Journal of Cardiology, 2014, 30, 1588-1594.	1.7	44
52	Compensatory enlargement of the left main coronary artery. Coronary Artery Disease, 2014, 25, 98-103.	0.7	11
53	LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes. Pancreas, 2014, 43, 1223-1231.	1.1	54

Comparison of Procedural Complications With Versus Without Interventional Cardiology54Fellows-in-Training During Contemporary Percutaneous Coronary Intervention. American Journal of1.61Cardiology, 2014, 113, 44-48.

#	Article	IF	CITATIONS
55	Coronary Revascularization Strategies in Patients With Diabetes and Multivessel Coronary Artery Disease. Journal of the American College of Cardiology, 2014, 64, 1198-1201.	2.8	7
56	Blood Transfusion During Acute Myocardial Infarction. Journal of the American College of Cardiology, 2014, 64, 811-819.	2.8	42
57	Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. American Heart Journal, 2013, 166, 823-830.e5.	2.7	182
58	Comparison of costs between transradial and transfemoral percutaneous coronary intervention: A cohort analysis from the Premier research database. American Heart Journal, 2013, 165, 303-309.e2.	2.7	58
59	Costs of Transradial Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2013, 6, 827-834.	2.9	96
60	Pre-Procedural Estimate of Individualized Bleeding Risk Impacts Physicians' Utilization of Bivalirudin During Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2013, 61, 1847-1852.	2.8	37
61	Comparison of Bivalirudin and Radial Access Across a Spectrum of Preprocedural Risk of Bleeding in Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2013, 6, 347-353.	3.9	32
62	Association Between Bleeding Events and In-hospital Mortality After Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2013, 309, 1022.	7.4	235
63	Management of Hyperglycemia with the Administration of Intravenous Exenatide to Patients in the Cardiac Intensive Care Unit. Endocrine Practice, 2013, 19, 81-90.	2.1	44
64	Relation Between Angiographic Lesion Severity, Vulnerable Plaque Morphology and Future Adverse Cardiac Events (from the Providing Regional Observations to Study Predictors of Events in the) Tj ETQq0 0 0 rgBT	/@øerlock	14 03 Tf 50 37
65	Does clinical presentation affect outcome among patients with acute coronary syndromes undergoing percutaneous coronary intervention? Insights from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree study. American Heart Journal, 2012, 164, 561-567.	2.7	6
66	Temporal Trends in and Factors Associated With Bleeding Complications Among Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2012, 59, 1861-1869.	2.8	129
67	Percutaneous Coronary Intervention Use in the United States. JACC: Cardiovascular Interventions, 2012, 5, 229-235.	2.9	50
68	Relationship Between Palpography and Virtual Histology in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Imaging, 2012, 5, S19-S27.	5.3	23
69	Characteristics and Clinical Significance of Angiographically Mild Lesions in Acute Coronary Syndromes. JACC: Cardiovascular Imaging, 2012, 5, S86-S94.	5.3	23
70	Plaque Composition and Clinical Outcomes in Acute Coronary Syndrome Patients With Metabolic Syndrome or Diabetes. JACC: Cardiovascular Imaging, 2012, 5, S42-S52.	5.3	113
71	Stratification of risk in thin cap fibroatheromas using peak plaque stress estimates from idealized finite element models. Medical Engineering and Physics, 2012, 34, 1330-1338.	1.7	8
72	A Prospective Natural-History Study of Coronary Atherosclerosis. New England Journal of Medicine, 2011, 364, 226-235.	27.0	2,721

#	Article	IF	CITATIONS
73	Comparison of Bleeding Complications Using Arterial Closure Device Versus Manual Compression by Propensity Matching in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2011, 107, 1619-1623.	1.6	12
74	Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 191-197.	2.9	229
75	Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies. Diabetes and Vascular Disease Research, 2011, 8, 237-240.	2.0	101
76	Percutaneous transluminal angioplasty: Association between depressive symptoms and diminished health status benefits. Vascular Medicine, 2011, 16, 260-266.	1.5	24
77	Revascularization Trumps Medicine for Patients With Type 2 Diabetes Mellitus and Chronic Angina (or) Tj ETQq1	1 0.78431 1.6	4 ₃ gBT /Over
78	Tissue characterisation of atherosclerotic plaque in the left main: an in vivo intravascular ultrasound radiofrequency data analysis. EuroIntervention, 2011, 7, 347-352.	3.2	20
79	Association Between Use of Bleeding Avoidance Strategies and Risk of Periprocedural Bleeding Among Patients Undergoing Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2010, 303, 2156.	7.4	264
80	Cost-Effectiveness of Targeting Patients Undergoing Percutaneous Coronary Intervention for Therapy With Bivalirudin Versus Heparin Monotherapy According to Predicted Risk of Bleeding. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 358-365.	2.2	35
81	Acute Coronary Syndrome in the Patient with Diabetes: Is the Management Different?. Current Cardiology Reports, 2010, 12, 321-329.	2.9	10
82	Incidence, Correlates, and Outcomes of Acute, Hospital-Acquired Anemia in Patients With Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 337-346.	2.2	91
83	The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes and Vascular Disease Research, 2010, 7, 119-130.	2.0	52
84	Diabetes mellitus is associated with plaque classified as thin cap fibroatheroma: an intravascular ultrasound study. Diabetes and Vascular Disease Research, 2010, 7, 14-19.	2.0	19
85	Do systemic risk factors impact invasive findings from virtual histology? Insights from the international virtual histology registry. European Heart Journal, 2010, 31, 196-202.	2.2	37
86	Plaque Burden With Composition?. Journal of the American College of Cardiology, 2010, 55, 983-985.	2.8	0
87	Bleeding in Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2009, 2, 222-229.	3.9	278
88	Diabetes Duration Is Associated With Increased Thin-Cap Fibroatheroma Detected by Intravascular Ultrasound With Virtual Histology. Circulation: Cardiovascular Interventions, 2009, 2, 543-548.	3.9	59
89	Chronic Total Occlusion Angioplasty in the United States. JACC: Cardiovascular Interventions, 2009, 2, 479-486.	2.9	259
90	Drug-Eluting Stents and the Use of Percutaneous Coronary Intervention Among Patients With Class I Indications for Coronary Artery Bypass Surgery Undergoing Index Revascularization. JACC: Cardiovascular Interventions, 2009, 2, 614-621.	2.9	31

#	Article	IF	CITATIONS
91	Intravascular ultrasound measures of coronary atherosclerosis are associated with the Framingham risk score: an analysis from a global IVUS registry. EuroIntervention, 2009, 5, 212-218.	3.2	27
92	Improvement in Survival Following Successful Percutaneous Coronary Intervention of Coronary Chronic Total Occlusions: Variability by Target Vessel. JACC: Cardiovascular Interventions, 2008, 1, 295-302.	2.9	126
93	Outcomes of 1,090 Consecutive, Elective, Nonselected Percutaneous Coronary Interventions at a Community Hospital Without Onsite Cardiac Surgery. American Journal of Cardiology, 2008, 101, 53-57.	1.6	29
94	Glucometrics in Patients Hospitalized With Acute Myocardial Infarction. Circulation, 2008, 117, 1018-1027.	1.6	349
95	Low Adiponectin Levels Are Associated With Atherogenic Dyslipidemia and Lipid-Rich Plaque in Nondiabetic Coronary Arteries. Diabetes Care, 2008, 31, 989-994.	8.6	49
96	Limitations to the use of virtual histology-intravascular ultrasound to detect vulnerable plaque. European Heart Journal, 2007, 28, 1783-1784.	2.2	25
97	Quantifying Improvement in Symptoms, Functioning, and Quality of Life After Peripheral Endovascular Revascularization. Circulation, 2007, 115, 569-575.	1.6	50
98	Intravascular ultrasound radiofrequency analysis of coronary atherosclerosis: an emerging technology for the assessment of vulnerable plaque. European Heart Journal, 2007, 28, 1283-1288.	2.2	69
99	Comparison of Myocardial Reperfusion in Patients Undergoing Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction With Versus Without Diabetes Mellitus (from) Tj ETQq1 1 C).7 8.4 314 r	gBJ9/Overloc
100	Peripheral Arterial Disease in Patients With Diabetes. Journal of the American College of Cardiology, 2006, 47, 921-929.	2.8	430
101	Success rates of percutaneous coronary intervention of chronic total occlusions and long-term survival in patients with diabetes mellitus. Diabetes and Vascular Disease Research, 2006, 3, 45-51.	2.0	29
102	Suspected Acute Coronary Syndrome Patients With Diabetes and Normal Troponin-I Levels Are at Risk for Early and Late Death: Identification of a new high-risk acute coronary syndrome population. Diabetes Care, 2006, 29, 1931-1932.	8.6	11
103	Metabolic syndrome-mediated inflammation following elective percutaneous coronary intervention. Diabetes and Vascular Disease Research, 2005, 2, 31-36.	2.0	8
104	Diabetes and percutaneous coronary intervention in the setting of an acute coronary syndrome. Diabetes and Vascular Disease Research, 2005, 2, 128-135.	2.0	6
105	Diabetes mellitus and vascular risk: continuing the quest for the elusive keystone. Diabetes and Vascular Disease Research, 2005, 2, 7-8.	2.0	1
106	Diabetes and Percutaneous Coronary Revascularization in the Drug-Eluting Stent Era. Herz, 2004, 29, 542-50.	1.1	1
107	Improving the pharmacological regimen for patients with diabetes mellitus. Reviews in Cardiovascular Medicine, 2004, 5, 139-47.	1.4	0
108	Diabetes mellitus is associated with a shift in the temporal risk profile of inhospital death after percutaneous coronary intervention: An analysis of 25,223 patients over 20 years. American Heart Journal, 2003, 145, 270-277.	2.7	48

#	Article	IF	CITATIONS
109	Receptor for AGE (RAGE) Mediates Neointimal Formation in Response to Arterial Injury. Circulation, 2003, 107, 2238-2243.	1.6	168
110	Myonecrosis following isolated coronary artery bypass grafting is common and associated with an increased risk of long-term mortality. European Heart Journal, 2003, 24, 1323-1328.	2.2	17
111	Improving in-hospital mortality in the setting of an increasing risk profile among patients undergoing catheter-based reperfusion for an acute myocardial infarction without cardiogenic shock. Journal of Invasive Cardiology, 2003, 15, 711-6.	0.4	6
112	Outcomes of Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Grafting. Circulation, 2002, 105, 322-327.	1.6	53
113	Review: The pathogenesis of type 2 diabetes and cardiovascular disease. British Journal of Diabetes and Vascular Disease, 2002, 2, 350-356.	0.6	2
114	Is a high hematocrit level good for patients with heart failure?. Journal of the American College of Cardiology, 2002, 39, 1703-1704.	2.8	0
115	Optimizing the diabetic formulary: beyond aspirin and insulin. Journal of the American College of Cardiology, 2002, 40, 652-661.	2.8	26
116	Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. American Journal of Cardiology, 2002, 90, 625-628.	1.6	376
117	Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. Journal of the American College of Cardiology, 2001, 38, 409-414.	2.8	593
118	Neointimal Hyperplasia After Arterial Injury Is Increased in a Rat Model of Non–Insulin-Dependent Diabetes Mellitus. Circulation, 2001, 104, 815-819.	1.6	107
119	Enhanced Efficacy of Eptifibatide Administration in Patients With Acute Coronary Syndrome Requiring In-Hospital Coronary Artery Bypass Grafting. Circulation, 2000, 102, 2952-2958.	1.6	56
120	Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting. American Heart Journal, 2000, 139, 939-944.	2.7	36
121	Abciximab reduces mortality in diabetics following percutaneous coronary intervention. Journal of the American College of Cardiology, 2000, 35, 922-928.	2.8	312
122	Optimizing the Percutaneous Interventional Outcomes for Patients With Diabetes Mellitus. Circulation, 1999, 100, 2477-2484.	1.6	272
123	The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. Journal of the American College of Cardiology, 1999, 33, 1269-1277.	2.8	60